| 1. | Tamoxifen approved by fda for marketing as a treatment drug
Fda批准他末昔芬作为治疗药物进入市场 |
| 2. | Effects of raloxifene on homocysteine and serum lipids in postmenopausal women
雷洛昔芬对绝经后妇女同型半胱氨酸及血脂的影响 |
| 3. | Effects of ethanol extract of sinomenium acutum on acute cardiac allograft rejection and peripharal levels of il - 2 and il - 10 in rats
雷洛昔芬对去卵巢大鼠骨组织雌激素受体亚型表达的影响 |
| 4. | Breast cancer preention trial begins , testing tamoxifen , a cancer treatment drug , as a preentie agent in women at increased risk of the disease
乳腺癌预防试验开始,证实治疗药物他莫昔芬在高风险女性人群中的预防作用 |
| 5. | Breast cancer prevention trial begins , testing tamoxifen , a cancer treatment drug , as a preventive agent in women at increased risk of the disease
乳腺癌预防试验开始,证实治疗药物他莫昔芬在高风险女性人群中的预防作用 |
| 6. | 1998 women at increased risk of deeloping breast cancer shown to reduce the chance of deeloping breast cancer by half by taking tamoxifen in the breast cancer preention trial
1998年,他莫昔芬乳腺癌预防试验表明高风险患者的发病机会降低一半 |
| 7. | Conclusions the recurrence score has been vakidated as quantifying the kikekihood of distant recurrence in tamoxifen - treated patients with node - negative ? estrogen - receptor - positive breast cancer
结论研究证实复发评分可量化淋巴结阴性、雌激素受体阳性、接受他莫昔芬治疗的乳腺癌患者的远处复发可能性。 |
| 8. | A second trial compares five years of femara to five years of tamoxifen , and to the sequence of two years of femara and three years of tamoxifen or the reverse - two years of tamoxifen and three years of femara
另一试验将5年弗隆治疗分别与5年他莫昔芬治疗，先2年弗隆后3年他莫昔芬治疗或先2年他莫昔芬后3年弗隆治疗，进行了比较。 |
| 9. | One study is a multinational adjuvant ( post - operative ) clinical trial evaluating disease - free and overall survival in women with breast cancer who take femara after having remained disease - free with five years of tamoxifen therapy
一项研究是多国辅药（术后）临床试验，用以评估乳癌患者服用弗隆后的无瘤生存率和整体生存率，这些女患者之前已进行了5年的他莫昔芬治疗，一直未发病。 |
